Recombinant Human C10orf54 protein (Myc Tag, His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

Myc Tag, His Tag

Activity

not tested

Cat no : Eg0017

---

Validation Data Gallery

• 

  Purity of Recombinant Human C10orf54 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <1.0 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human C10orf54 protein Phe33-Ala194 (Accession# Q9H7M9 ) with a Myc tag and a His tag at the C-terminus.
• GeneID: 64115
• Accession: Q9H7M9
• PredictedSize: 23.7 kDa
• Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

VISTA (V-domain Ig suppressor of T cell activation), also known as C10orf54, B7-H5, PD-1H and Dies1, is a member of the immune checkpoints of the B7 family that shares significant homology with PD-L1 and PD-L2. VISTA is predominantly expressed on haematopoietic cells, myeloid cells, and weakly expressed on T cells. It can act as a ligand expressed on antigen presenting cells (APCs), and also functions as an coinhibitory receptor for CD4+ T cells. VISTA exerts negative regulatory functions by suppressing the activation, proliferation, and cytokine secretion of T cells. VISTA plays an important role in tumor progression and immune escape and can be used as a predictor for diagnosis or immunotherapy of cancer.

References:

1.Yuan, Long et al. Trends in immunology vol. 42,3 (2021): 209-227.
2.Mulati, Kumuluzi et al. British journal of cancer vol. 120,1 (2019): 115-127. 
3.Shi, Tongguo et al. Journal of immunology research vol. 2022, (2022): 3013185.
4.Emaldi, Maite et al. iScience vol. 27,9 (2024): 110587.